Neumarker

Neumarker is proud to participate in the Foundation for the National Institutes of Health’s (FNIH) Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative, a landmark public- private collaboration focused on transforming how depression is defined, diagnosed, and treated. The multi-year effort will generate one of the most comprehensive datasets ever assembled to identify biological subtypes of depression and enable more personalized, precision-driven care.

As a consortium partner, Neumarker will contribute its expertise in AI-powered EEG biomarker development alongside leading academic institutions, life sciences companies, patient advocacy organizations, and government partners. MAP-D represents an important step toward improving patient outcomes by advancing objective biomarkers that can help guide diagnosis, treatment selection, and future therapeutic development.

MAP-D Press Release: https://fnih.org/our-programs/multi-modal-assessment-phenotyping-depression/

About FNIH MAP-D: https://fnih.org/our-programs/multi-modal-assessment-phenotyping-depression/

About Neumarker
Neumarker is a precision neurotechnology company developing AI-powered EEG biomarkers to improve the diagnosis, prognosis, and treatment of neurological and psychiatric disorders. By combining advanced machine learning with large-scale, multimodal clinical datasets, Neumarker is building objective biomarkers that help clinicians make more informed treatment decisions and accelerate the development of precision therapies.

Through collaborations with leading healthcare systems, academic medical centers, life sciences organizations, and public-private research initiatives, Neumarker is advancing scalable, clinically validated solutions across epilepsy, depression, autism spectrum disorder, and other CNS conditions. To learn more, visit www.neumarker.ai.